Addex Therapeutics Ltd.
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
ADXN | SW
Overview
Corporate Details
- ISIN(s):
- CH0029850754 (+2 more)
- LEI:
- 89450068Y9KVP2MQGH86
- Country:
- Switzerland
- Address:
- c/o Addex Pharma SA, Chemin des Aulx 12, 1228 Plan-Les-Ouates
- Sector:
- Manufacturing
Description
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-08 01:00 |
Addex to Present at the 2025 Swiss Equities Baader Conference
|
English | 5.2 KB | ||
| 2024-11-22 01:00 |
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
English | 17.7 KB | ||
| 2024-11-11 01:00 |
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second…
|
English | 7.1 KB | ||
| 2024-09-30 02:00 |
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results …
|
English | 17.2 KB | ||
| 2024-09-19 02:00 |
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net…
|
English | 7.0 KB | ||
| 2024-09-04 02:00 |
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Confe…
|
English | 5.2 KB | ||
| 2024-08-27 02:00 |
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Mo…
|
English | 7.4 KB | ||
| 2024-07-22 02:00 |
Addex’s Partner Discontinues ADX71149 development in Epilepsy
|
English | 8.2 KB | ||
| 2024-07-15 02:00 |
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth …
|
English | 7.2 KB | ||
| 2024-07-12 02:00 |
Addex To Present at the Thirteenth London International Cough Symposium (13th L…
|
English | 5.8 KB | ||
| 2024-07-01 02:00 |
Addex Shareholders Approve All Resolutions at Annual General Meeting
|
English | 6.7 KB | ||
| 2024-06-06 02:00 |
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Upd…
|
English | 13.6 KB | ||
| 2024-06-05 02:00 |
Addex Convenes Annual General Meeting 2024
|
English | 9.2 KB | ||
| 2024-05-31 02:00 |
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Cal…
|
English | 6.1 KB | ||
| 2024-05-08 02:00 |
Addex to Present at Bio€quity Europe 2024
|
English | 5.3 KB |
Automate Your Workflow. Get a real-time feed of all Addex Therapeutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Addex Therapeutics Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Addex Therapeutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-27 | N/A | Executive member | Buy | None | 301,345.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 53,760.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 45,450.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 44,856.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 24,423.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 5,487.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 3,927.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 2,150.00 CHF |
Peer Companies
